Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (134) Arrow Down
Filter Results: (134) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (235)
    • News  (71)
    • Research  (134)
    • Events  (1)
    • Multimedia  (3)
  • Faculty Publications  (94)

Show Results For

  • All HBS Web  (235)
    • News  (71)
    • Research  (134)
    • Events  (1)
    • Multimedia  (3)
  • Faculty Publications  (94)
← Page 5 of 134 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • 2021
  • Working Paper

The Health Costs of Cost-Sharing

By: Amitabh Chandra, Evan Flack and Ziad Obermeyer
We use the design of Medicare’s prescription drug benefit program to demonstrate three facts about the health consequences of cost-sharing. First, we show that an as-if-random increase of 33.6% in out-of-pocket price (11.0 percentage points (p.p.) change in... View Details
Keywords: Cost-sharing; Impact; Health Care and Treatment; Insurance; Health; Consumer Behavior
Citation
Read Now
Related
Chandra, Amitabh, Evan Flack, and Ziad Obermeyer. "The Health Costs of Cost-Sharing." NBER Working Paper Series, No. 28439, February 2021.
  • June 2004 (Revised November 2004)
  • Case

Acorda Therapeutics: Rebuilding the Spinal Cord

Acorda is an early-stage life science start-up with a promising product that is close to reaching the market (Phase III clinical trials). The company is grappling with how to expand its portfolio of molecules to make the business more sustainable. It faces classic... View Details
Keywords: Decision Making; Science-Based Business; Health Testing and Trials; Business Startups; Product Development; Biotechnology Industry
Citation
Find at Harvard
Related
Enriquez-Cabot, Juan, Jonathan West, Marina Kolesnik, and Fiona Murray. "Acorda Therapeutics: Rebuilding the Spinal Cord." Harvard Business School Case 604-014, June 2004. (Revised November 2004.)
  • 2023
  • Working Paper

Market Exclusivity and Innovation: Evidence From Antibiotics

By: Edward Kong and Olivia Zhao
The US incentivizes drug innovation via patents as well as market exclusivity periods awarded by the US Food and Drug Administration. We estimate the causal effects of extending market exclusivity for an important drug class: antibiotics. Using a... View Details
Keywords: Health Testing and Trials; Innovation and Invention; Motivation and Incentives; Government Administration; Government Legislation; Pharmaceutical Industry; United States
Citation
SSRN
Related
Kong, Edward, and Olivia Zhao. "Market Exclusivity and Innovation: Evidence From Antibiotics." Working Paper, December 2023.
  • June 2023 (Revised July 2024)
  • Case

Biogen and the Aduhelm Melee

By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.

This... View Details
Keywords: Health Testing and Trials; Governing Rules, Regulations, and Reforms; Valuation; Product Development; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023. (Revised July 2024.)
  • 19 Dec 2017
  • First Look

New Research and Ideas, December 19, 2017

trials. As a result, this could change the types of products that can be profitably brought to market. To better understand the landscape of precision medicines, we use a comprehensive database of over 130,000 global clinical View Details
Keywords: Carmen Nobel
  • December 2006 (Revised August 2008)
  • Case

Pervasis Therapeutics, Inc.

By: Robert F. Higgins and Virginia Fuller
In May 2005, Steve Bollinger was about to become president and chief operating officer of Pervasis Therapeutics, a small cell therapy start-up in Cambridge, Mass. If proven successful, Pervasis' product, Vascugel, could change the way vascular disease is treated and... View Details
Keywords: Business Startups; Venture Capital; Financial Strategy; Governing Rules, Regulations, and Reforms; Health Care and Treatment; Health Testing and Trials; Health Industry; Cambridge
Citation
Educators
Purchase
Related
Higgins, Robert F., and Virginia Fuller. "Pervasis Therapeutics, Inc." Harvard Business School Case 807-026, December 2006. (Revised August 2008.)
  • September 2020
  • Case

Minerva 2004: Discovery

By: John R. Wells and Benjamin Weinstock
After nearly five years in operation, Doctor Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), was reflecting on the company’s next steps. In a few short years, she and her small team had managed to develop a nanoparticle process for... View Details
Keywords: Entrepreneurship; Financing and Loans; Strategy; Decision Choices and Conditions; Biotechnology Industry
Citation
Educators
Purchase
Related
Wells, John R., and Benjamin Weinstock. "Minerva 2004: Discovery." Harvard Business School Case 721-389, September 2020.
  • June 2008 (Revised July 2008)
  • Case

The Miami Project to Cure Paralysis

By: Robert Steven Kaplan, Christopher Marquis and Brent Kazan
Marc Buoniconti is the co-founder of the Miami Project to Cure Paralysis, a nonprofit medical research organization. The project was founded in 1985 by Marc and his father Nick, a former Hall of Fame football player, when Marc suffered a spinal cord injury. In 2007,... View Details
Keywords: Investment; Philanthropy and Charitable Giving; Health Testing and Trials; Leadership; Growth and Development Strategy; Mission and Purpose; Research and Development; Nonprofit Organizations; Health Industry; Miami
Citation
Educators
Purchase
Related
Kaplan, Robert Steven, Christopher Marquis, and Brent Kazan. "The Miami Project to Cure Paralysis." Harvard Business School Case 408-003, June 2008. (Revised July 2008.)
  • Article

Czech Mate: Expropriation and Investor Protection in a Converging World

By: Mihir A. Desai and Alberto Moel
This paper examines the expropriation of a foreign investor by a local partner and the subsequent resolution of that case through international arbitration in favor of the investor. Despite the investor's 99% interest in joint venture, the local partner managed to... View Details
Keywords: Joint Ventures; Capital Markets; Foreign Direct Investment; Geographic Location; Multinational Firms and Management; Governance Controls; Courts and Trials; Rights; Czech Republic; United States
Citation
SSRN
Find at Harvard
Related
Desai, Mihir A., and Alberto Moel. "Czech Mate: Expropriation and Investor Protection in a Converging World." Review of Finance 12, no. 1 (2008): 221–251. (This paper is a revised version of ECGI Working Paper No. 62/2004.)
  • March 2023
  • Case

Moderna

By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details
Keywords: Health Pandemics; Research and Development; Digital Transformation; Health Testing and Trials; Biotechnology Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Iansiti, Marco, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen, and Dave Habeeb. "Moderna." Harvard Business School Multimedia/Video Case 623-703, March 2023. (Click here to access this case.)
  • June 2014 (Revised February 2017)
  • Case

Kathy Giusti and the Multiple Myeloma Research Foundation

By: Richard G. Hamermesh, Joshua D. Margolis and Matthew G. Preble
What do you do when your rising professional career is cut short by an unexpected cancer diagnosis? Kathy Giusti shifted careers, built a new organization that transformed how cancer research is done, and now faces the challenge of sustaining the organization and its... View Details
Keywords: Philanthropy; Philanthropy Funding; Entrepreneurship; Health Care; Management Styles; Personalized Medicine; Health Care Outcomes; Cancer; Cancer Care In The U.S.; Personal Care; Leadership; Leading Change; Social Entrepreneurship; Philanthropy and Charitable Giving; Health Care and Treatment; Leadership Style; Management Style; Management Skills; Growth and Development Strategy; Business Strategy; Health; Health Industry; United States; Canada; Spain
Citation
Educators
Purchase
Related
Hamermesh, Richard G., Joshua D. Margolis, and Matthew G. Preble. "Kathy Giusti and the Multiple Myeloma Research Foundation." Harvard Business School Case 814-026, June 2014. (Revised February 2017.)
  • January 2009 (Revised July 2009)
  • Case

Targanta Therapeutics: Hitting a Moving Target

By: Arthur A. Daemmrich
This case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful... View Details
Keywords: Decision Choices and Conditions; Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Business and Government Relations; Business Strategy; Biotechnology Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Daemmrich, Arthur A. "Targanta Therapeutics: Hitting a Moving Target." Harvard Business School Case 709-002, January 2009. (Revised July 2009.)
  • 10 Oct 2007
  • First Look

First Look: First Look: October 10

numbered. What the industry must embrace in its place is a business model based on a larger portfolio of targeted—and therefore more effective and profitable—treatments, not a limited palette of one-size-fits-all drugs. The current regulatory environment overemphasizes... View Details
Keywords: Martha Lagace
  • 13 Jan 2003
  • Research & Ideas

The Subconscious Mind of the Consumer (And How To Reach It)

Additionally, there is now a lot of evidence that personal interviews yield deep insights that can't be obtained from focus groups. So, my preference is to conduct in-depth, one-on-one interviews that are enriched by using various techniques from View Details
Keywords: by Manda Mahoney
  • 21 Feb 2018
  • Research & Ideas

When a Competitor Abandons the Market, Should You Advance or Retreat?

Administration. He looked most closely at decisions made during phase two clinical trials—the period when diseased patients are treated with the test drug and results are compared with patients randomly receiving a placebo. The View Details
Keywords: by Rachel Layne; Pharmaceutical; Health
  • 12 Jun 2018
  • Research & Ideas

In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?

The rewards of research Do those investments pay off? Researchers examined revenue, stock returns, clinical value, and the population impacted by the novel drug. And they quantified the risk of those investments, coming up with a... View Details
Keywords: by Rachel Layne; Health; Pharmaceutical
  • 28 Mar 2023
  • Research & Ideas

The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation

spent $83 billion on research and development (R&D) in 2019, according to a 2021 report from the nonpartisan Congressional Budget Office (CBO). The median cost to develop one drug was $900 million, with half of that amount going toward funding the necessary rounds... View Details
Keywords: by Kasandra Brabaw; Pharmaceutical
  • 14 Nov 2017
  • First Look

New Research and Ideas: November 14, 2017

expensive. How can health care organizations change this? One key is to prioritize quality improvement over cost cutting. By harnessing IT to help design better clinical practices, it’s possible to achieve better patient outcomes and... View Details
Keywords: Carmen Nobel
  • 27 Feb 2019
  • Research & Ideas

The Hidden Cost of a Product Recall

significant, the researchers say. Competitors ramp up major innovation efforts in response to rival recalls. Large-scale new product development projects cost more, take longer to complete, and require specialized teams to manage complex processes, such as View Details
Keywords: by Danielle Kost; Manufacturing; Consumer Products; Auto; Medical Devices & Supplies
  • 10 Aug 2015
  • Research & Ideas

New Medical Devices Get To Patients Too Slowly

devices—first on animals and then on humans in clinical trials. "For new chemical drugs, it's typically relatively straightforward to know how to move toward approval," says Stern. "Clinical trials take time... View Details
Keywords: by Michael Blanding; Health; Technology
  • ←
  • 5
  • 6
  • 7
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.